ABSTRACT
Objective To investigate the changes of inflammatory factors,vascular endothelial function and blood lipid in patients with unstable angina pectoris.Methods From March 2017 to March 2018,270 patients with unstable angina pectoris treated in Taizhou Central Hospital were selected as the observation group,and 100 healthy persons from March 2017 to March 2018 were selected as the control group.The contents of CRP,IL-6 and TNF-alpha were determined by enzyme linked immunosorbent assay (ELISA).The content of ET-1 was measured by radioimmunoassay.The content of NO was determined by the method of nitric acid reduction.The contment of blood lipid was measured by automatic biochemical analyzer.The contents of four items of blood lipid were determined by automatic biochemical analyzer.Results The levels of serum CRP[(6.07 ± 1.25) mg/L],IL-6 [(10.42 ± 2.56) mg/L] and TNF-alpha[(3.24 ±0.58) mg/L] in the observation group were higher than those in the control group[(1.04 ± 0.32) mg/L,(2.79 ±0.78) mg/L,(1.16 ±0.34) mg/L] (t =39.729,29.283,33.760,all P ＜0.05).The level of ET-1 in the observation group was (126.42 ±20.91)ng/L,which was higher than that in the control group[(68.93 ± 8.79) ng/L] (t =26.619,P ＜ 0.05),while the level of NO in the observation group [(40.38 ± 7.65) μmol/L] was lower than that in the control group [(67.42 ± 10.42) μmol/L] (t =27.224,P ＜ 0.05).The levels of TC [(5.63 ±0.84) mmol/L],LDL-C [(3.78 ± 0.81) mmol/L] and TG [(1.39 ± 0.29) mmol/L] in the observation group were higher than those in the control group [(4.10 ± 0.65)mtmol/L,(2.19 ± 0.42)mmol/L and (0.65 + 0.12) mmol/L],and the level of HDL-C in the observation group[(1.10 ± 0.21) mmol/L] was lower than that in the control group [(1.49 ± 0.17) mmol/L] (P ＜ 0.05).Conclusion Patients with unstable angina pectoris have obvious inflammatory reaction,vascular endothelial dysfunction and dyslipidemia.It is believed that inflammatory reaction,vascular endothelial function and blood lipid are closely related to the occurrence and development of unstable angina pectoris of coronary heart disease.It is worthy of clinical reference.
ABSTRACT
Drug laws were collected by summaring recent Chinese medicine treatment of lung cancer in etiology and pathogenesis , diagnosis and treatment, special disease post-party.It showed parts of the overall and the overall direction of lung cancer treatment.Especially in each lung cancer treatment of internal treatment experience.The traditional Chinese medicine in treatment of lung cancer lesions were stable , survival period longer and survival quality good advantage.For the treatment of modern western medicine, adverse effects, such as surgery, radiotherapy, chemotherapy and other adverse effects, the quality of life of patients can be improved by certain therapeutic method , which can provide protection for the treatment of the body. All aspects of the comprehensive treatment of lung cancer with Chinese medicine , pay attention to traditional Chinese medicine therapy for lung cancer attaches great importance to the protection of the patient’s quality of life, followed by the disease to improve treatment, overall see the prospect of traditional Chinese medicine in the treatment of lung cancer .
ABSTRACT
Objective To discuss the effect and safety about large dosage of tilofiban injection into coronary artery in patients with ST-segment elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Methods A prospective study was conducted. Two hundred and eighteen patients with STEMI admitted into Cardiology Department of Taizhou Central Hospital were enrolled. According to the difference in dosage, they were divided into a large dosage tilofiban group (102 cases) and a routine dosage tilofiban group (116 cases). In both groups, they received the injection of load dosage of tilofiban into coronary artery during they underwent primary PCI, the load dosage being 25μg/kg in the large dosage group, and 10μg/kg in the routine dosage group. Afterwards, the dosage was kept on 0.15μg·kg-1·min-1 in both groups lasting for 18-24 hours. The flow of thrombolysis in myocardial infarction (TIMI) immediately after PCI, the return of ST-segment after operation for 2 hours, the rate of bleeding events, the rate of major adverse cardiac event [MACE, including death, re-infarction and target vessel revascularization (TVR)] and prognosis after operation for 30 days were observed. Results The ratios of the immediate reflow of TIMI 3 grade after operation and the return of ST-segment after operation for 2 hours in the large dosage tirofiban group were higher than those in the routine dosage tirofiban group [the ratio of the reflow of TIMI 3 grade:92.16%(94/102) vs. 81.90%(95/116), the ratio of the return of ST-segment after operation for 2 hours:89.22%(91/102) vs. 73.28%(85/116), both P 0.05]. Conclusion The injection of a large dosage of tilofiban into a coronary artery in patients with STEMI undergoing primary PCI is an effective and safe method to allow them to get more clinical benefits.